Scientists have discovered how to transform the immune system’s own sleeping cells inside tumors into aggressive cancer-fighting warriors with a single injection.

Story Highlights

• KAIST researchers developed an injection that reprograms tumor-dwelling immune cells into cancer killers on-site
• The breakthrough bypasses complex cell extraction procedures used in current CAR-T therapies
• Mouse studies showed significant melanoma tumor reduction and body-wide immune activation
• Treatment targets solid tumors that have resisted previous immunotherapy approaches

The Sleeping Giant Problem in Cancer Treatment

Inside every solid tumor lurk millions of immune cells called macrophages, but they have been essentially drugged into submission by the cancer itself. These cellular security guards, designed by nature to eliminate threats, instead become accomplices helping tumors grow and spread. Professor Ji-Ho Park at KAIST recognized this biological betrayal as the key obstacle preventing effective treatment of solid cancers like melanoma, breast cancer, and brain tumors.

Traditional CAR-T cell therapy has achieved remarkable success against blood cancers, with some patients surviving over a decade. However, solid tumors present a fortress-like environment where the same approach fails miserably. The tumor’s microenvironment actively suppresses any immune response, turning potential allies into enemies.

The Trojan Horse Solution

Park’s team engineered a clever workaround using lipid nanoparticles loaded with messenger RNA and immune-activating compounds. When injected directly into tumors, these microscopic packages are absorbed by the sleeping macrophages. The cells then begin producing CAR proteins, transforming into “CAR-macrophages” programmed specifically to recognize and destroy cancer cells.

This approach eliminates the weeks-long process of extracting a patient’s immune cells, genetically modifying them in laboratories, and reinfusing them back into the body. Instead, the reprogramming happens exactly where it is needed most. The converted macrophages not only attack cancer directly but also wake up other immune cells in the surrounding area, creating a cascading defensive response.

Injection turns sleeping tumor immune cells into cancer fighters https://t.co/fjALv5jz3V

— Un1v3rs0 Z3r0 (@Un1v3rs0Z3r0) January 11, 2026

Racing Beyond Current Limitations

The timing of this breakthrough aligns with other revolutionary advances in cancer immunotherapy. Earlier in 2025, USC researchers developed ultrasound-activated CAR-T cells that remain active for five days instead of the typical 24 hours. Indiana University scientists discovered how to reprogram regulatory T-cells, converting immune system suppressors into cancer fighters.

These parallel developments signal a fundamental shift in cancer treatment philosophy. Rather than fighting the immune system’s complexity, researchers are learning to harness and redirect its existing machinery. The KAIST injection represents the most direct approach yet, requiring no external cell manipulation or complex timing protocols.

Promise Meets Practical Reality

In melanoma mouse models, the injected CAR-macrophages demonstrated impressive tumor suppression and triggered immune responses throughout the body. The treatment’s localized delivery means the CAR proteins degrade naturally outside the tumor area, potentially reducing side effects that plague other immunotherapies. This built-in safety mechanism addresses one of the major concerns about CAR-based treatments.

However, the critical question remains whether this laboratory success will translate to human patients. Every cancer immunotherapy breakthrough of the past decade has faced the harsh reality that mouse models, while encouraging, do not guarantee human efficacy. The complexity of human immune systems and the heterogeneity of individual tumors present challenges that no laboratory can fully replicate.

Watch;

Meet My Healthy Doc – instant answers, anytime, anywhere.

Sources:

New smart immune cells: a breakthrough for long-lasting tumor destruction
Injection turns sleeping tumor immune cells into cancer fighters
IU researchers reprogram immune cells to fight cancer
7 breakthroughs in patient-centric oncology care in 2026